<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845646</url>
  </required_header>
  <id_info>
    <org_study_id>ASC41-105</org_study_id>
    <nct_id>NCT04845646</nct_id>
  </id_info>
  <brief_title>DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.</brief_title>
  <official_title>Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gannex Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gannex Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of itraconazole, a strong&#xD;
      inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A,&#xD;
      CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of ASC41, a THR beta agonist tables in&#xD;
      healthy subjects. The PK, Safety and Tolerability of ASC 41 in Subjects with NAFLD will also&#xD;
      be evaluated. Approximately 24 subjects including 16 healthy volunteers (HVs) and 8 subjects&#xD;
      with NAFLD will be enrolled. This study consists of 3 cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multiarm study in HVs and subjects with NAFLD is designed to further characterize the&#xD;
      PK, safety and tolerability of ASC41. Part I of the study will assess the effect of&#xD;
      itraconazole and phenytoin on the single-dose PK of ASC41 in HVs. Part II of the study will&#xD;
      evaluate the PK, safety and tolerability of a single dose of ASC41 in subjects with NAFLD.&#xD;
      The pharmacokinetics of ASC41 and its metabolite ASC41-A will be assessed in both parts I and&#xD;
      II. The secondary objective of the study is to characterize the safety and tolerability of&#xD;
      oral ASC41 in subjects in the U.S. with NAFLD and in HVs. Approximately 24 male and female&#xD;
      participants will be enrolled. This study consists of 3 cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of ASC41</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of ASC41</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Evaluate the Peak Plasma Concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ASC41</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Evaluate the Terminal-Phase Half-Life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of ASC41</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Evaluate the Apparent Systemic Clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of ASC41</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Evaluate the Apparent Volume of Distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline up to 24 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>ASC41 + Itraconazole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11.&#xD;
Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASC41 + Phenytoin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19.&#xD;
Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASC41 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC41</intervention_name>
    <description>5mg/tablet</description>
    <arm_group_label>ASC41 + Itraconazole group</arm_group_label>
    <arm_group_label>ASC41 + Phenytoin group</arm_group_label>
    <arm_group_label>ASC41 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>200mg/capsule</description>
    <arm_group_label>ASC41 + Itraconazole group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>300mg/capsule</description>
    <arm_group_label>ASC41 + Phenytoin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Part I Healthy subjects between 18 to 55 years of age&#xD;
&#xD;
          -  Part II&#xD;
&#xD;
               1. Subjects with NAFLD&#xD;
&#xD;
               2. Subjects between 18 to 65 years of age&#xD;
&#xD;
        Key Exclusion criteria:&#xD;
&#xD;
          -  Part I&#xD;
&#xD;
               1. A history of thyroid disease&#xD;
&#xD;
               2. A history of, or current liver disease, or liver injuries&#xD;
&#xD;
               3. Platelet count &lt;150,000/mcL&#xD;
&#xD;
               4. INR&gt; 1.2&#xD;
&#xD;
               5. History of, or current electrocardiogram (ECG) abnormalities, arrhythmias or&#xD;
                  heart valve diseases judged to be clinically significant by the investigator&#xD;
&#xD;
          -  Part II&#xD;
&#xD;
               1. A history of thyroid disease&#xD;
&#xD;
               2. Current or history of cirrhosis or decompensated liver disease&#xD;
&#xD;
               3. AST or ALT &gt; 5X ULN&#xD;
&#xD;
               4. DBIL &gt; ULN&#xD;
&#xD;
               5. Acute or chronic liver disease other than NAFLD&#xD;
&#xD;
               6. A history of bariatric surgery&#xD;
&#xD;
               7. HbA1c &gt;9.5% at screening&#xD;
&#xD;
               8. Testosterone or estrogen replacement therapy&#xD;
&#xD;
               9. Inducers or inhibitors of CYP3A4, including herbal therapies such as St John's&#xD;
                  Wort (CYP3A4 Inducer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ICON early Phase Services LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>NAFLD</keyword>
  <keyword>DDI (Drug-Drug Interaction)</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Phenytoin</keyword>
  <keyword>THR beta agonist</keyword>
  <keyword>ASC41</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

